GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)
NCT05356104 on ClinicalTrials.gov · last registry update 2026-06-05
Recruiting now, toward 110 participants. Due to report May 2027, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Change of Brain Peak Width of Skeletonized Mean Diffusivity. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 25 May 2022 — 4 years so far.
- Status
- RECRUITING
- Phase
- P2
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Chinese University of Hong Kong
- Sponsor type
- Other
- Enrollment
- 110
- Started
- 2022-05-25
- Primary completion
- 2027-05 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change of Brain Peak Width of Skeletonized Mean Diffusivity
Conditions studied
Cerebral Small Vessel Disease
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.